Photosensitization Study in Androgenetic Alopecia

• ClinicalTrials.gov Identifier: NCT02791243
• Recruitment Status: Completed
• First Posted: June 6, 2016
• Last Update Posted: May 18, 2017
• Sponsor: Polichem S.A.
• Information provided by (Responsible Party): Polichem S.A.

Study Description

Brief Summary:

This study evaluates the potential for induction of photosensitization by P-3074 0.25% finasteride cutaneous solution compared to that of placebo vehicle cutaneous solution and a negative control (0.9% sodium chloride, NaCl)

Condition or disease	Intervention/treatment	Phase
Androgenetic Alopecia	Drug: Finasteride 0.25%; Drug: Placebo for Finasteride 0.25%; Drug: Negative Control	Phase 1

Detailed Description:

Healthy male volunteers, drawn from the general population, will be treated with P-3074 solution, placebo vehicle control and 0.9% sodium chloride USP (negative control) by using 6 induction applications on the back area and Ultraviolet A (UVA)/Ultraviolet B (UVB) irradiations during the 3 week induction period, a 10 day rest period, and a challenge phase of a 24-hour patch application, UVA and UVB irradiation followed by evaluation of photosensitization over the subsequent 72 hours.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 58 participants
• Allocation: Randomized
• Intervention Model: Factorial Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Within-subject, Randomized, Evaluator-blinded, Vehicle-controlled Study to Assess the Photosensitization Potential of Finasteride Cutaneous Solution(P-3074) in Human Subjects
• Actual Study Start Date: May 9, 2016
• Actual Primary Completion Date: June 2016
• Actual Study Completion Date: June 27, 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: Finasteride 0.25%; approximately 0.2 ml of P-3074 (0.25% finasteride)	Drug: Finasteride 0.25%; Cutaneous solution of finasteride 0.25%; Other Name: P-3074
Placebo Comparator: Placebo for Finasteride 0.25%; approximately 0.2 ml of the vehicle cutaneous solution	Drug: Placebo for Finasteride 0.25%; vehicle cutaneous solution of P-3074; Other Name: vehicle cutaneous solution
Negative Control; approximately 0.2 ml of 0.9% aqueous NaCl	Drug: Negative Control; 0.9% aqueous NaCl; Other Name: 0.9% aqueous NaCl

Outcome Measures

Primary Outcome Measures :

1. Potential for induction of photosensitization [ Time Frame: from day 4 to day 42 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Males aged 18 to 65.
2. Good general health, as assessed by verbal medical history and brief physical examination of the skin.
3. Fitzpatrick Skin Type I-IV, determined by interview at screening.
4. Willing to use a double-barrier methods (for example, a condom or a diaphragm plus spermicide) during sexual intercourse with a female partner while participating in the study.
5. Male subjects will need to confirm method and length of time for method of birth control for female partners.
6. Fully informed of the risks of entering the study and willing to provide written consent to enter the study.
7. Willing to follow study rules, which include: no sun exposure (for example, no swimming, sunbathing, or tanning beds), avoidance of activities that would cause excessive sweating, no use of lotions, creams, or oils on the back area
8. Must be willing not to change current brand of personal care products such as soaps, body washes, laundry detergent, body sprays, body spritzes, etc. while participating on the study.

Exclusion Criteria:

1. MED ≤ 2.5 SED for Fitzpatrick Skin Types I and II or MED ≤ 4.0 SED for Fitzpatrick Skin Types III and IV
2. Type I Insulin-dependent diabetes
3. Mastectomy for cancer involving removal of lymph nodes draining the test site.
4. Clinically significant skin diseases which may contraindicate participation, including psoriasis, eczema, atopic dermatitis, and active skin cancer.
5. Use of any photosensitizing medications or supplements, such as but not limited to sulfa drugs, tetracyclines, phenothiazines, thiazides, antiemetics and St. John's Wort.
6. Any medical conditions caused or affected by sunlight (UV), such as but not limited to solar urticarial and polymorphous light eruptions.
7. Active immunologic disorders.
8. Routine use of anti-inflammatory, immunosuppressive or antihistamine medications (81 mg aspirin is acceptable).
9. Participation in a patch test or soap chamber test within the past 4 weeks.
10. History of significant sensitivity or allergy to adhesive bandages, tapes, etc.
11. Use of finasteride (oral and/or topical), within 6 months prior to the screening visit.
12. Contraindications to finasteride therapy or intolerance of finasteride.
13. History of sensitivity to skin solution products.
14. Hair, tattoos, pigmentation, scars, moles or other conditions at the areas to be patched that may interfere with patch application, tolerability, or postapplication evaluations.
15. Participation in a clinical trial or receipt of an investigational medication within 4 weeks of the study.
16. Current treatment with allergy injections.
17. History of severe asthma.
18. Chronic or active liver disease [alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5x upper limit of normal (ULN)]
19. Neutrophils < 1500 cells/mm3
20. Clinically significant chronic illness, which could place the subject at increased risk during participation or result in inappropriate dermal response during the study in the opinion of the Investigator.
21. History of alcohol or drug abuse within 1 year of the study.
22. Any condition the Investigator believes would interfere with the evaluation of the subject, or may put the subject at undue risk.
23. Judged by the investigator to be unsuitable for any reason.

Contacts and Locations

Locations

United Kingdom

Princeton Consumer Research Inc.

Chelmsford,, Essex, United Kingdom, CM2 6UA

Sponsors and Collaborators

Polichem S.A.

Investigators

• Principal Investigator: Michael Carr, MD; Princeton Consumer Research Inc.

More Information

• Responsible Party: Polichem S.A.
• ClinicalTrials.gov Identifier: NCT02791243
• Other Study ID Numbers: PM1542
• First Posted: June 6, 2016
• Last Update Posted: May 18, 2017
• Last Verified: May 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Alopecia; Alopecia Areata; Photosensitivity Disorders; Hypotrichosis; Hair Diseases; Skin Diseases; Pathological Conditions, Anatomical; Finasteride; 5-alpha Reductase Inhibitors; Steroid Synthesis Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Urological Agents